糖尿病

互動

參與AIFA（Agenzia Italiana del Farmaco－義大利藥品管理局）的公眾諮詢、區域糖尿病工作小組，以及對取得CGM（持續葡萄糖監測）感測器、胰島素幫浦和創新藥物的貢獻。

互動

閱讀原始引言

我們定期倡導改善巴基斯坦全國的胰島素可及性與可用性。2024年3月，我們舉辦了一場倡議圓桌會議，隨後與DRAP（巴基斯坦藥品監管局）進行了多次交流。

We regularly advocate for improved insulin accessibility and availability across Pakistan. In March 2024, we organized an advocacy roundtable, followed by multiple engagements with DRAP. Through these efforts, we highlighted the urgent need for the government to ensure consistent insulin access for people living with diabetes nationwide. By building strong people power and collective advocacy, we were able to drive meaningful government action. As a result, the government signed a contract for the local manufacturing of insulin, marking a major milestone in diabetes care in Pakistan. This public–private collaboration has since led to the launch of insulin products by two local pharmaceutical companies and the initiation of the Chief Minister Punjab Insulin Support Program, which is modeled after Meethi Zindagi’s Program of Insulin (POI).

行動與倡議

閱讀原始引言

與市政府及縣市衛生福利服務機構合作，將第2型糖尿病藥物納入免費藥品治療範圍。

Yhteydenpito kaupunkiin ja hyvinvointialueeseen maksuttoman lääkehoidon ulottamiseksi myös tyypin 2 diabeteslääkkeisiin.

行動與倡議

閱讀原始引言

將醫療器材（例如連續血糖監測儀和胰島素幫浦）納入全民健康保險給付項目。

연속 혈당 측정기, 인슐린 펌프 등의 의료 제품의 건강 보험 등재.